A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Trial Details
- NCT ID
- NCT06004336
- Phase
- PHASE2
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Cancer Type
- Kidney Cancer
- Interventions
- Pembrolizumab
- Radiation therapy
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- In order to be eligible for trial participation, patients must have:
- The participant provides written informed consent for the trial.
- Pathologically confirmed diagnosis of RCC with a clear cell component.
- Be willing and able to undergo biopsy of a lesion planned for definitive RT. If a lesion amenable to SBRT was biopsied prior to enrollment, this ma…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Kidney Cancer Trials on Trialify →